Twelfth meeting of the Intergovernmental Negotiating Body (INB)
On 4 November 2024 in Geneva, IFPMA delivered a statement at the twelfth meeting of the Intergovernmental Negotiating Body (INB).
Thank you for this opportunity to continue being engaged in the INB process.
The innovative pharmaceutical industry remains committed to achieving a Pandemic Agreement that works, addressing the needs of countries while enabling the private sector to innovate and respond effectively to future pandemics. For this to happen, countries must tackle critical barriers for equitable access, such as insufficient financing for procurement on behalf of low-income countries, inadequate demand forecast, regulatory barriers, insufficient absorption capacity, and export restrictions. Intellectual property needs to be respected, and transfer of technology must always be voluntary and on mutually agreed terms.
We recognize that INB 12 is a critical milestone in the negotiations of the Pandemic Agreement and remain committed to sharing our experience and providing our expertise to support this process, whether through a special session of the World Health Assembly this year or if the negotiations extend to next year.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
